Bronchogen: Respiratory Bioregulator
Last updated: October 2026
Bronchogen (Ala-Glu-Asp-Leu) is a Khavinson bioregulator tetrapeptide designed for respiratory tissue research. At 446.45 g/mol it is a very small peptide; its developers propose it acts directly on bronchial cells by binding DNA, a mechanism that is still unproven.
🧪 Buy Bronchogen at Swiss Chems →AEDL
Weight
Bronchial Tissue
What Is Bronchogen?
Bronchogen belongs to the Khavinson bioregulator family — short peptides their developers propose act by binding DNA to modulate gene expression in specific tissues. Bronchogen has been studied in human bronchial epithelial cell cultures and in a rat model of chronic obstructive pulmonary disease (COPD). Published papers give its sequence as Ala-Glu-Asp-Leu (AEDL) or Ala-Asp-Glu-Leu (ADEL), and Khavinson co-authored papers using each name; the amino acids, and so the molecular weight, are the same.
In cell-free lab tests, Bronchogen bound DNA and preferred short DNA sequences containing CTG (PMID 22117547, a study of short peptides and their interaction with DNA; its HeLa cell-entry tests used other Khavinson peptides, not Bronchogen). No study has shown that it targets DNA specific to lung tissue.
In human embryonic bronchial epithelial cell cultures, the peptide changed expression of genes linked to bronchial epithelium differentiation, such as NKX2-1 and SCGB1A1 (PMID 25015171, a Lung study of gene expression and protein synthesis in bronchial epithelium). No study we found measured bronchodilation or airflow.
In rats with COPD induced by nitrogen dioxide exposure, a month of Bronchogen normalized the proinflammatory cytokine profile in lung lavage fluid and reduced neutrophilic inflammation (PMID 26468022, peptide therapy in rats with obstructive lung pathology). These are animal results, not human data.
In the same rat COPD model, Bronchogen reversed signs of bronchial epithelial remodeling such as goblet cell hyperplasia, and restored ciliated cells (PMID 26468022). In cell culture, its effects on differentiation factors were stronger in older, late-passage bronchial cells (PMID 22808515, peptides stimulating cell differentiation during aging).
What the Research Shows
Context: Bronchogen research is early-stage and limited. Data comes from cell-culture and cell-free lab studies and a rat COPD model, mostly from Russian research groups, often with Khavinson as a co-author. We found no human clinical trials indexed in PubMed. The evidence base is thinner than for some other Khavinson peptides.
Side Effects & Safety Profile
Study Citations
Self-Assessment
Who Researches Bronchogen?
This Research Is Commonly Explored By People Who...
- Are interested in peptide-based approaches to respiratory health
- Follow the Khavinson bioregulator research program
- Want to understand tissue-specific peptide interactions with lung cells
- Are exploring bioregulators as a class (often alongside Epitalon, Vilon, Testagen)
This Research May Not Be Relevant If...
- You want clinical trial data — none has been published for Bronchogen
- You need proven respiratory treatments — see your doctor
- You want well-characterized mechanisms — data is very preliminary
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide — $19 (normally $29) →
New to peptides? Start with the $19 Buyer’s Playbook →
Key Takeaways
- Tetrapeptide (AEDL) developed for respiratory-tissue research
- Part of the Khavinson bioregulator peptide class
- Reduced lung inflammation and epithelial remodeling in a rat COPD model (PMID 26468022)
- Binds DNA in cell-free lab tests (PMID 21240358, DNA thermostability study)
- No human clinical trials found in PubMed
- Very limited published research specific to Bronchogen
- Exact mechanism and efficacy not validated
- No evidence that it relaxes airways (bronchodilation)
- Whether it enters lung cells in the body is unproven
- Not FDA approved — research only
- No long-term safety data
🔬 Verified Research Source
Bronchogen is sold for research use by Swiss Chems, our affiliate partner.
Affiliate links — support HighPeptides at no extra cost.
Research Supplies
Tools and supplies relevant to this research area.
Affiliate links — support HighPeptides at no extra cost. As an Amazon Associate, HighPeptides earns from qualifying purchases.
Bronchogen is NOT FDA approved and is available only for research purposes. Evidence is very limited. This page is for educational purposes only. Not medical advice. Research Only
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.